Gilead Sciences, Inc.

The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

Gilead Sciences Inc raised its full-year profit forecast on Monday, as a recent resurgence in COVID-19 cases boosted demand for its COVID-19 treatment, remdesivir.

Gilead Sciences Inc raised its full-year profit forecast on Monday, boosted by increased sales of COVID-19 treatment remdesivir, as hospitalization and treatment rates were higher than expected given the most recent surge in cases.

The U.S. government must face claims by Gilead Sciences Inc that it breached contracts with the drugmaker by obtaining and asserting patents related to the company's HIV preventive drug Truvada, a federal judge has ruled.

Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval for its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval of its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

Europe's drugs regulator on Friday recommended changing some terms of the conditional approval given to antiviral drug remdesivir as a COVID-19 treatment, to make clear the conditions under which it can be used.

Gilead Sciences Inc said on Thursday it will acquire MYR GmbH for about 1.15 billion euros ($1.39 billion) in cash, giving it access to the German biotech company's treatment for a severe form of viral hepatitis.

Gilead Sciences Inc said on Thursday it will acquire MYR GmbH for about 1.15 billion euros ($1.39 billion) in cash, giving it access to the German biotech company's treatment for a severe form of viral hepatitis.

Gilead's remdesivir should not be used for patients hospitalised with COVID-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said on Friday.

The European Commission on Friday said there had been no change in the authorised uses of Gilead's remdesivir after the World Health Organization advised against using the antiviral for treating hospitalised COVID-19 patients.

The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat COVID-19 patients.

Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness.

Germany's health minister defended on Tuesday his decision to purchase additional supplies of remdesivir for treating COVID-19, saying Gilead's antiviral drug was useful especially early in the course of the disease.

Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug's effectiveness in treating COVID-19.

Russian drugmaker Pharmasyntez has asked the Kremlin to allow it to produce a generic version of U.S. COVID-19 drug remdesivir, used to treat U.S. President Donald Trump, despite lacking a patent to do so, the firm's director said on Monday.

Russian drugmaker Pharmasyntez has asked the Kremlin for permission to produce a generic version of U.S. firm Gilead Sciences's COVID-19 treatment remdesivir without а patent, the Vedomosti newspaper reported on Monday.

Gilead Sciences Inc <GILD.O> on Wednesday cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID-19.

Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.